What is the projected market valuation for the GCC companion diagnostics-oncology market by 2035?

The projected market valuation for the GCC companion diagnostics-oncology market is $625.13 Million by 2035. Read More

What was the overall market valuation in 2024?

The overall market valuation in 2024 was $285.63 Million. Read More

What is the expected CAGR for the GCC companion diagnostics-oncology market during the forecast period 2025 - 2035?

The expected CAGR for the GCC companion diagnostics-oncology market during the forecast period 2025 - 2035 is 7.38%. Read More

Which technology segment is projected to have the highest valuation in 2035?

The Next Generation Sequencing technology segment is projected to reach $200.0 Million by 2035. Read More

What are the key applications driving the GCC companion diagnostics-oncology market?

Key applications include Predictive Testing, which is expected to reach $180.0 Million by 2035. Read More

Which end user segment is anticipated to show significant growth by 2035?

The Hospitals end user segment is anticipated to grow to $200.0 Million by 2035. Read More

What is the valuation range for the Polymerase Chain Reaction technology segment?

The valuation range for the Polymerase Chain Reaction technology segment is projected between $70.0 Million and $150.0 Million. Read More

Which company is a key player in the GCC companion diagnostics-oncology market?

Roche is one of the key players in the GCC companion diagnostics-oncology market. Read More

What is the expected valuation for the Patient Stratification application by 2035?

The expected valuation for the Patient Stratification application is $160.0 Million by 2035. Read More

How does the market for Genetic Tests compare to other test types in 2035?

The market for Genetic Tests is projected to reach $200.0 Million, indicating strong performance compared to other test types. Read More

GCC Companion Diagnostics Oncology Market

ID: MRFR/MED/48455-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

GCC Companion Diagnostics Oncology Market Research Report By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry), By Applications (Therapeutic Monitoring, Patient Stratification, Predictive Testing, Disease Diagnosis), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), and By Test Type (Genetic Tests, Protein Biomarker Tests, MicroRNA Tests, Pathological Analysis) - Growth & Industry Forecast 2025 To 2035

GCC Companion Diagnostics Oncology Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Technology (USD Million)
  1. 4.1.1 Next Generation Sequencing
  2. 4.1.2 Polymerase Chain Reaction
  3. 4.1.3 In Situ Hybridization
  4. 4.1.4 Immunohistochemistry
2. 4.2 Pharmaceutical, BY Applications (USD Million)
  1. 4.2.1 Therapeutic Monitoring
  2. 4.2.2 Patient Stratification
  3. 4.2.3 Predictive Testing
  4. 4.2.4 Disease Diagnosis
3. 4.3 Pharmaceutical, BY End User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Laboratories
  3. 4.3.3 Research Institutions
  4. 4.3.4 Pharmaceutical Companies
4. 4.4 Pharmaceutical, BY Test Type (USD Million)
  1. 4.4.1 Genetic Tests
  2. 4.4.2 Protein Biomarker Tests
  3. 4.4.3 MicroRNA Tests
  4. 4.4.4 Pathological Analysis
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Thermo Fisher Scientific (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Abbott (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Agilent Technologies (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Illumina (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Qiagen (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Myriad Genetics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Hologic (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 BioMérieux (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY TECHNOLOGY
3. 6.3 GCC MARKET ANALYSIS BY APPLICATIONS
4. 6.4 GCC MARKET ANALYSIS BY END USER
5. 6.5 GCC MARKET ANALYSIS BY TEST TYPE
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY APPLICATIONS, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY APPLICATIONS, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY TEST TYPE, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY TEST TYPE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATIONS, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
  4. 7.2.4 BY TEST TYPE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Pharmaceutical Market Segmentation

Pharmaceutical By Technology (USD Million, 2025-2035)

Next Generation Sequencing
Polymerase Chain Reaction
In Situ Hybridization
Immunohistochemistry

Pharmaceutical By Applications (USD Million, 2025-2035)

Therapeutic Monitoring
Patient Stratification
Predictive Testing
Disease Diagnosis

Pharmaceutical By End User (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions
Pharmaceutical Companies

Pharmaceutical By Test Type (USD Million, 2025-2035)

Genetic Tests
Protein Biomarker Tests
MicroRNA Tests
Pathological Analysis

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”